Lasa Supergenerics per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−₹3.30−₹6.80−₹2.95−₹4.34−₹15.42
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−₹3.30−₹6.80−₹2.95−₹4.34−₹15.42
₹9.90₹9.90₹16.71₹19.30₹23.61
₹1.27₹5.02₹28.43₹20.82₹25.86
—−₹4.56−₹0.56₹0.43−₹6.69
−₹4.56−₹4.56−₹0.56₹0.29−₹7.65
5.05.05.05.05.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health
₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹23.4 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-15.42-4.34-2.95-6.80-3.30
Diluted EPS-15.42-4.34-2.95-6.80-3.30
Book Value per Share23.6119.3016.719.909.90
Revenue per Share25.8620.8228.435.021.27
Cash Flow per Share-6.690.43-0.56-4.56—
Free Cash Flow per Share-7.650.29-0.56-4.56-4.56
Shares Outstanding (cr)5.05.05.05.05.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.